



(51) International Patent Classification:

C07D 411/12 (2006.01) **A61K 31/4535** (2006.01)
C07D 411/14 (2006.01) **A61K 31/454** (2006.01)
C07D 413/14 (2006.01) **A61K 31/506** (2006.01)
C07D 417/14 (2006.01)

(21) International Application Number:

PCT/IN2010/000418

(22) International Filing Date:

17 June 2010 (17.06.2010)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1458/MUM/2009 18 June 2009 (18.06.2009) IN

(71) **Applicant** (for all designated States except US): **CADILA HEALTHCARE LIMITED** [IN/IN]; Zydus Tower, Satellite Cross Roads, Ahmedabad 380 015 (IN).

(72) **Inventors; and**

(75) **Inventors/Applicants** (for US only): **PINGALI, Harikishore** [IN/IN]; Cadila Healthcare Limited, Zydus Tower, Satellite Cross Roads, Ahmedabad 380 015 (IN). **ZAWARE, Pandurang** [IN/IN]; Cadila Healthcare Limited, Zydus Tower, Satellite Cross Roads, Ahmedabad 380 015 (IN). **JAIN, Mukul** [IN/IN]; Cadila Healthcare Limited, Zydus Tower, Satellite Cross Roads, Ahmedabad 380 015 (IN).

(74) **Agent:** **SUBRAMANIAM, Hariharan**; Nataraj & Associates, E-556, Greater Kailash-II, New Delhi 110 048 (IN).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
 — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) **Title:** NOVEL GPR 119 AGONISTS

(57) **Abstract:** The present invention relates to novel GPR 119 agonists of the general Formula (I), their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, enantiomers, stereoisomers, and polymorphs. The invention also relates to processes for the preparation of the compounds of the invention, pharmaceutical compositions containing the compounds and to methods for treating one or both of diabetes and obesity using the compounds of the invention. The present invention is directed to G-protein coupled receptor (GPCR) agonists that are useful for the treatment of obesity, diabetes and related metabolic disorders.